NovaBridge Biosciences (NBP) Current Leases (2019 - 2025)

NovaBridge Biosciences (NBP) has 7 years of Current Leases data on file, last reported at $891000.0 in Q4 2025.

• Quarterly Current Leases rose 9.19% year-over-year to $891000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $891000.0 (up 9.19% YoY) and the FY2025 annual result came in at $891000.0, up 9.19% from the prior year.
• Current Leases rose to $891000.0 in Q4 2025 per NBP's latest filing, from $872000.0 in the prior quarter.
• Across five years, Current Leases topped out at $4.8 billion in Q4 2021 and bottomed at $737000.0 in Q2 2024.
• The 5-year median for Current Leases is $891000.0 (2025), against an average of $370.8 million.
• The widest annual swing landed in 2021, when Current Leases surged 394417.06%; it then tumbled 99.93% in 2022.
• Tracing NBP's Current Leases over 5 years: stood at $4.8 billion in 2021, then plunged by 99.93% to $3.4 million in 2022, then retreated by 9.76% to $3.0 million in 2023, then sank by 73.16% to $816000.0 in 2024, then increased by 9.19% to $891000.0 in 2025.
• Per Business Quant, the three latest NBP Current Leases figures stand at $891000.0 (Q4 2025), $872000.0 (Q3 2025), and $853000.0 (Q2 2025).

Peer Comparison